Malignant melanoma
Malignant melanoma is common in white people. Queen S-Land in Australia is a well-known high-incidence area of malignant melanoma in the world. The incidence of malignant melanoma in my country is not high, but due to the lack of awareness of its severity by doctors and patients, it is usually too late when seeking medical treatment, and the treatment effect is extremely unsatisfactory. This disease is common in people aged 30 to 60 years old. Spity, a rare juvenile malignant melanoma, reported 13 cases, aged 1.5 to 12 years old. Younger people generally have a lower degree of malignancy and a better prognosis after surgical resection. There is almost no difference in the gender of the onset of the disease, but the location of the lesion is related to gender. Those who occur on the trunk are more common in men, and those who occur on the limbs are more common in women than men, especially facial freckle melanoma, which is more common in elderly women.
-
Site of disease:
skin
-
Infectious :
Not contagious
-
Frequent population:
Mental workers, head-down workers
-
Related symptoms:
Edema
pigmented skin lesions
skin moles
skin moles
anterior chamber pigmentation
-
Concurrent disease:
Related Drugs
Dacarbazine for injection
Indication: This product is used to treat malignant melanoma
Manufacturer:
Shanxi PUDE Pharmaceutical Co., Ltd.
Dacarbazine for injection
Indication: This product is used to treat malignant melanoma
Manufacturer:
Fresenius Kabi (Wuhan) Pharmaceutical Co., Ltd.
Dacarbazine for injection
Indication: This product is used to treat malignant melanoma
Manufacturer:
Fresenius Kabi (Wuhan) Pharmaceutical Co., Ltd.
Fotemustine for injection
Indication: Primary brain tumours and disseminated malignant melanoma (including intracerebral sites).
Manufacturer:
Shandong Ruiying Pioneer Pharmaceutical Co., Ltd.
Fotemustine for injection
Indication: For the treatment of primary malignant brain tumors and disseminated malignant melanoma (including intracerebral sites).
Fotemustine
Indication: 1. For the treatment of primary brain tumors and disseminated malignant melanoma (including intracerebral sites). 2. For the treatment of malignant melanoma and advanced cancer. 3. For the treatment of primary brain tumors that are not suitable for surgery. 4. For the treatment of multiple lymph node metastatic malignant tumors and leukemia.